Tenecteplase Boosts Late-Window Reperfusion but Not 90-Day Function
For neurology pharmacists, this Chinese phase IIb trial shows 0.25 mg/kg tenecteplase improves imaging-defined reperfusion in the 4.5- to 24-hour window without changing clinical outcomes.
📅 Journal publication: Feb 2025(online Jan 2, 2025)·Last updated: Jul 18, 2026
Tenecteplase enhances late-window stroke reperfusion without added hemorrhage risk.
Extending thrombolysis treatment to 24 hours with imaging selection could increase options for stroke patients. Tenecteplase showed a 33.3% major reperfusion rate compared to 10.8% with best medical treatment, without increased hemorrhagic risk. While tenecteplase improves reperfusion in an extended window, the 90-day clinical outcomes did not improve; further large-scale studies are needed. Tenecteplase extends thrombolysis efficacy for stroke up to 24 hours with specific imaging criteria.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Cheng X, Hong L, Lin L, Churilov L, Ling Y, Yang N, Fu J, Lu G, Yue Y, Zhang J, Wang F, Wang Z, Zhao Y, Zhou X, Peng Z, Wu D, Zhao L, Zhai Q, Yu X, Fang Q, Shao X, Tang Y, Zhang D, Geng Y, Zhang Y, Fan B, Zhang B, Yin C, Chen Y, Zhang Y, Liu X, Li S, Yang L, Parsons M, Dong Q, CHABLIS-T II Collaborators
Citation:Cheng X, Hong L, Lin L, et al. Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial. Stroke. 2025;56(2):344-354. doi:10.1161/STROKEAHA.124.048375